Biodexa Pharmaceuticals (NASDAQ: BDRX)

Last close As at 04/10/2024

0.99

−0.03 (−2.94%)

Market capitalisation

5m

Edison Investment Research is terminating coverage on Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More
Midatech Pharma_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (16.1) (22.7) (85.2)
Relative (19.6) (26.6) (88.2)
52 week high/low US$8.0/US$0.7

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2022A 0.7 (8.6) (8.5) (6.30) N/A N/A
2023A 0.4 (7.7) (7.5) (5.30) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free